Full-Time

Director of Financial Planning & Analysis

Posted on 5/11/2026

Antares Therapeutics

Antares Therapeutics

51-200 employees

Develops precision oncology therapeutics and pipelines

Compensation Overview

$190k - $240k/yr

Boston, MA, USA + 1 more

More locations: New York, NY, USA

In Person

Category
Finance & Banking (1)
Required Skills
Forecasting
Data Analysis
Financial Modeling
Requirements
  • Bachelor’s degree in Finance, Accounting, Economics, or a related field
  • 8+ years of progressive FP&A experience, including hands-on ownership of planning, forecasting, and financial modeling
  • Prior experience in strategy, management consulting, or finance advisory roles, paired with experience fully embedded within a biotech or life sciences company
  • Strong understanding of biotech financial drivers, particularly R&D and clinical development spending
  • Hands-on experience with Workday Adaptive Planning (required)
  • Advanced financial modeling, forecasting, and data analysis skills
  • Proven ability to independently engage with functional leaders and translate complex financial data into clear, actionable insights
  • Highly collaborative, proactive, and comfortable operating with minimal supervision in a fast-paced, evolving environment
  • Ability to operate as an individual contributor without direct reports
Responsibilities
  • Serve as a strategic finance partner to functional leadership, providing financial insights to support investment decisions, portfolio prioritization, and long-range planning
  • Lead all aspects of budgeting, forecasting, and long-range financial planning, with a strong focus on R&D spend
  • Develop and maintain detailed financial models related to pipeline programs, development plans, and clinical milestones
  • Partner closely with Research, Development, Clinical, and Technical Operations leaders to align financial plans with scientific and operational objectives
  • Support scenario modeling and sensitivity analyses to inform strategic initiatives and corporate planning
  • Prepare board- and executive-level materials, including financial analyses, variance explanations, and strategic recommendations
  • Own and continuously enhance FP&A processes, tools, and reporting, with a strong emphasis on scalability and accuracy
  • Serve as a subject matter expert for Workday Adaptive Planning, driving adoption, optimization, and effective use across the organization
  • Support ad hoc financial analyses related to partnering, business development, and corporate strategy as needed
Desired Qualifications
  • MBA or CPA strongly preferred
  • Oncology experience and prior partnership with R&D leadership is a major plus
  • Prior experience in strategy, management consulting, or finance advisory roles, paired with experience fully embedded within a biotech or life sciences company

Antares Therapeutics focuses on developing precision oncology medicines. It advances targeted cancer therapies by leveraging Scorpion Therapeutics’ discovery platform acquired by Lilly, using its validated pipeline and leadership with deep oncology experience to guide research and development. The company works by identifying cancer-specific targets and creating therapies that act on those targets, followed by clinical validation and eventual commercialization in advanced cancer indications. Its differentiation comes from access to Scorpion’s discovery capabilities, the support and resources of Lilly, and a leadership team with experience in oncology and life sciences, enabling a science-driven approach to push the boundaries of precision medicine. Antares aims to shape the future of precision oncology by delivering transformative treatments that can improve outcomes for cancer patients.

Company Size

51-200

Company Stage

Series A

Total Funding

$177M

Headquarters

Boston, Massachusetts

Founded

2025

Simplify Jobs

Simplify's Take

What believers are saying

  • Lead program enters clinical trials in 2026, enabling partnerships like Scorpion's $2.5B Lilly deal.
  • Mutant EGFR inhibitors PFL-721 and PFL-241 licensed to Pierre Fabre for global commercialization.
  • PARP1 inhibitor MOMA-989 partnered with Moma Therapeutics targets combination therapy demand.

What critics are saying

  • Preclinical R&D burns $177M Series A in 24-36 months before clinical data.
  • Most advanced program fails Phase 1 toxicity endpoints in 18-24 months.
  • AstraZeneca launches competing transcription factor drugs ahead of 2026 using 2022 IP.

What makes Antares Therapeutics unique

  • Antares pioneers small molecules targeting undruggable transcription factors in oncology.
  • Leverages Scorpion's computational chemistry and mass spectrometry for novel binding pockets.
  • Advances first-in-class assets from 2022 AstraZeneca transcription factor collaboration.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Antares Therapeutics who can refer or advise you

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

6%

2 year growth

6%
Business Wire
Jun 11th, 2025
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases

Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched...

Pipeline Review
Jun 10th, 2025
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases

BOSTON, MA, USA I June 10, 2025 I Antares Therapeutics, Inc. ("Antares"), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched today with $177 million in Series A financing.